Time, Route, and Host Factors: Where the Evidence Gets Thin

The two-dose JYNNEOS/MVA-BN evidence is reassuring, but the details become less settled when the question changes from “does vaccination help?” to “which route, how long, and for whom?” This chapter examines those modifiers in breakthrough mpox data. The goal is not to pick a universal route or declare a precise expiration date for protection. It is to distinguish an observed signal from a causal conclusion and to keep the population and host conditions attached to each claim.

That discipline matters because route, time, and health status are not interchangeable labels. A breakthrough after two intradermal doses is not the same observation as a breakthrough after two subcutaneous doses or a mixed schedule. A case occurring months after vaccination is not a direct measurement of antibody levels. A finding in people with well-controlled HIV cannot be extended automatically to people with unsuppressed HIV or other serious immune impairment. The sources offer useful clues, but they also show exactly where the clues stop.

Intradermal and subcutaneous observations do not form a head-to-head trial

The U.S. CDC report had route information for 139 of 271 fully vaccinated breakthrough cases. Among those records, 46% followed a heterologous schedule, meaning one subcutaneous and one intradermal dose; 32% followed two subcutaneous doses; and 22% followed two intradermal doses. The figures describe the route composition of reported breakthrough cases with complete route information. They do not show the infection rate for each route, because the report does not provide a comparable denominator of everyone who received each route.

That distinction is easy to miss. If 22% of breakthrough cases followed two intradermal doses, a reader might conclude that intradermal vaccination caused more or fewer infections. But the numerator is only the set of cases for which route was known. To compare routes as prevention strategies, we would need to know how many people received each schedule, their opportunities for exposure, when they were vaccinated, and how consistently infections were detected. Without those denominators, the route breakdown is descriptive rather than a route-specific effectiveness estimate.

The report does contain a time comparison within the route data. Among people who received the same route for both doses, the median interval from the second dose to illness onset was 363 days after two intradermal doses and 263 days after two subcutaneous doses. That difference was statistically significant. However, the report explicitly says that the implication is unknown. It does not establish that the intradermal route provides longer protection, that subcutaneous protection fades sooner, or that the groups had the same exposure pattern.

Why might the groups differ for reasons other than route? Intradermal vaccination was preferentially used during the peak of the outbreak when supplies were limited. People vaccinated then may have entered different exposure conditions from people vaccinated later, when the outbreak and public behavior had changed. The groups may also differ in why they were offered a particular route, how quickly they received both doses, and where their vaccination was documented. A longer time from dose two to illness could reflect route, campaign timing, or the way breakthrough cases were found. The table alone cannot separate those explanations.

The Swedish case series adds a different kind of evidence. All MVA-BN doses in that study were administered intradermally, and vaccinated patients who developed mpox had lower median severity scores, fewer lesions, less spread, less mucosal involvement, fewer bacterial superinfections, and lower analgesic needs than the unvaccinated comparison group. This is useful evidence that an intradermal program was associated with clinically meaningful attenuation in the observed setting. It is not a direct comparison against a subcutaneous group.